idioPathic pulmonary fibrosis
ENV-IPF-101
STUDY OUTLINE
The study medication, ENV-101, acts on a protein, which is a compound made by the body, that is thought to be involved in the scarring of the lungs. By blocking this process, ENV-101 may slow progress of the disease, which may improve the symptoms of IPF.
This is a randomised double-blind study. This means that neither you nor your study doctor will know which dose of study medication you will be receiving. You will take a tablet of ENV-101 or placebo. These tablets will have the same appearance including colour and consistency.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0888 or email clinicaltrials@resphealth.uwa.edu.au.
ELIGIBILITY & REQUIREMENTS
- Aged 40 or older
- Confirmed diagnosis of Idiopathic Pulmonary Fibrosis within the last 5 years
WHAT'S INVOLVED
- The trial will run for a minimum of 24 weeks with a 2 week follow-up
- 9 clinic visits in Nedlands, plus one phone visit
- A full health check by our doctors and nurses
- Reimbursement for travel expenses
- Personalised health care with our doctors and nurses
PRINCIPAL INVESTIGATOR
Dr Vidya Navaratnam (Nedlands)
THIS CLINICAL TRIAL IS CURRENTLY CLOSED
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.